{
    "nct_id": "NCT03030183",
    "official_title": "A Phase 2 Multicenter, Open-Label, Uncontrolled Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of RA101495 in Subjects With Paroxysmal Nocturnal Hemoglobinuria Who Have an Inadequate Response to Eculizumab",
    "inclusion_criteria": "* Diagnosis of PNH by flow cytometry\n* Inadequate response to eculizumab defined as having received eculizumab for at least 6 months plus a documented LDH level â‰¥ 1.5 x the upper limit of normal (ULN) and/or the presence of a known C5 mutation conferring resistance to eculizumab\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* History of meningococcal disease\n* Current systemic infection or suspicion of active bacterial infection",
    "miscellaneous_criteria": ""
}